849
Participants
Start Date
May 22, 2023
Primary Completion Date
October 31, 2026
Study Completion Date
July 31, 2027
eftilagimod alpha
APC activator, MHC II agonist
Paclitaxel
paclitaxel will be given as standard of care (chemotherapy)
placebo
placebo matching eftilagimod alpha
Cliniques Universitaires Saint-Luc, Brussels
ARENSIA Exploratory Medicine Phase I Unit, Chisinau
Universitair Ziekenhuizen Antwerpen, Edegem
Grand Hopital de Charleroi - Hopital Notre Dame, Charleroi
Centre Hospitalier de l'Ardenne, Libramont
Hospital Universitario Reina Sofia, Córdoba
The George Washington University Cancer Center, Washington D.C.
Hospital Universitario de Jaén, Jaén
Unidad Ensayos Clínicos Oncología Fundació IRB Lleida, Lleida
START Madrid - FJD, Hospital Fundación Jiménez Diaz, Madrid
Hospital Universitario La Paz, Madrid
Carolina Blood and Cancer Care Associates, Rock Hill
Oncology Consultants, Houston
The University of Texas MD Anderson Cancer Center, Houston
The Oncology Institute, Whittier
AZ Sint-Jan Brugge Oostende av, Bruges
Clinique Saint-Pierre- Ottignies, Ottignies-Louvain-la-Neuve
ARENSIA Exploratory Medicine LLC, Tbilisi
Institut Català d'Oncologia, Badalona
VHIO - Hospital Vall d'Hebron, Barcelona
Hospital Clinic de Barcelona, Barcelona
Parc Taulí Hospital Universitari, Barcelona
Immutep S.A.S.
INDUSTRY